ATP Fund

Most venture capital is built around picking, but ATP Fund is built around translation. The Austin-based deep-tech firm describes itself as a venture catalyst, a phrase that captures its actual function more accurately than the standard label of seed investor. ATP focuses on early scientific founders who are moving research from a lab or institutional setting into a venture-backed company, and the fund’s structure, check sizes, and partner mix all reflect that translation problem rather than the more conventional problem of scaling a product-market-fit company from seed to Series A. For physician-scientists and clinician-engineers thinking about company formation around novel diagnostics, devices, or applied AI, ATP is one of the few US firms that takes the founding moment itself as the central object of work.

The investment thesis spans AI, biotech, medtech, cleantech, robotics, and cybersecurity, but the through-line is research translation rather than sector. ATP co-invests, which is a deliberate choice. The fund is structured to reduce friction for first-time scientific founders by partnering with other early-stage investors, sharing diligence load, and providing the operational scaffolding that researchers typically lack. The check size, which runs from roughly two hundred and fifty thousand to one million dollars, is calibrated to be additive within a syndicate rather than to lead an entire pre-seed or seed round. In practice this means ATP wants to be in the room with university tech transfer offices, federal grant programs, angel groups, and other deep-tech specialists. The fund will underwrite science risk and is comfortable with pre-revenue companies, but it expects founders to have made meaningful progress on the translation question itself: which problem in the world the research solves, why now, and what the first commercial wedge looks like.

The portfolio is small and tightly themed. DeteQt works in detection technology, Edoceo Devices builds medical devices, and Diligent Robotics is the most visible name in the portfolio, building socially intelligent service robots that have been deployed in hospital settings to handle non-clinical tasks for nursing staff. The Diligent investment is the clearest example of how ATP thinks about healthcare: not as a clinical AI bet but as a robotics and operational-AI bet that lands inside health systems. Founders pitching pure clinical-decision-support software will find a smaller surface area of fit; founders building hardware-software systems or applied AI in diagnostics, devices, or care operations will find more.

Check sizes between two hundred and fifty thousand and one million dollars, combined with co-investment-only positioning, place ATP firmly in the pre-seed and seed range with occasional Series A participation. The fund is geographically focused on the United States and Canada, with Austin as the operational center. For founders running a typical pre-seed round of one to three million dollars, ATP can credibly take a meaningful position alongside a lead, and the fund is particularly useful when the company benefits from Texas-based talent, federal lab connectivity, or the broader Austin deep-tech ecosystem. There is no published revenue requirement, and the deep-tech orientation means ATP is comfortable with multi-year horizons before commercial validation, provided the translation thesis is credible.

The team is intentionally weighted toward operators and scientists rather than pure financial investors. Kyle Cox serves as managing partner and runs the investment process. Bart Bohn partners on the ATP Foundation side, which extends the fund’s footprint into research-translation programs and ecosystem work. John Stockton is a venture partner with operating background, and Brian Huskinson, PhD, brings the scientific depth that the portfolio’s research-translation thesis demands. Safi Modi rounds out the team as venture associate. The structure is small and accessible, with a clear PhD-level partner on diligence for technical companies, which matters for founders pitching genuinely novel science.

The most effective path in is through other deep-tech co-investors, university tech transfer offices, federal lab partners, or Austin-area founder networks. ATP’s co-investment model means the fund is constantly in conversation with other early-stage investors, and a warm referral from a current or prospective syndicate partner carries significant weight. Founders affiliated with Texas institutions, including UT Austin and the broader research ecosystem, have a natural channel. Cold inbound through the website is possible but, as with most deep-tech funds, it converts best when the founder has a clear translation narrative and an existing co-investor in motion.

Founders should approach ATP when they are scientific or technical first-time founders translating research into a company, when the round is in the pre-seed to early-Series A range, when there is at least one other early-stage investor leaning in, and when the company sits in deep-tech, medtech, diagnostics, or applied AI. ATP is not the right fit for purely software-only digital health plays without scientific or hardware depth, nor for founders who need a single check to anchor a round. For the right research-translation company, the firm is one of the more thoughtful catalyst-style partners in the US deep-tech landscape.